Enrique de Álava, MD, PhD discusses the benefits of using NGS panels vs single-gene testing to guide treatment of non-small cell lung cancer patients (NSCLC) and explains the value of comprehensive genomic profiling (CGP) for accurate diagnosis and opportunities for precision medicine for patients with diagnostically challenging tumors like sarcomas and rare cancers. Enrique de Álava, MD, PhD is the head of the Department of Pathology at the Virgen del Rocío University Hospital, IBiS, University of Seville, Spain. Share this video in Spanish: https://youtu.be/gEOuSoNTjOU Learn more about in-house Comprehensive Genomic Profiling (CGP) and rare mutations: https://youtu.be/NErI9YCGcn4 Learn about in-house CGP including homologous recombination deficiency (HRD): https://youtu.be/qz9auYRPvV8 Subscribe to the Illumina video channel http://www.youtube.com/subscription_center?add_user=IlluminaInc A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond. View customer spotlight videos https://www.youtube.com/playlist?list=PLKRu7cmBQlajfheLzgbI4S7xBn7IDbt79 View Illumina webinars https://www.youtube.com/playlist?list=PLKRu7cmBQlahpXlnrrXlQw9itVJ8yHwUZ View Illumina support videos https://www.youtube.com/playlist?list=PLKRu7cmBQlajbm2KGsICWb-JOnusJfYvM LinkedIn: https://www.linkedin.com/company/illumina X: https://x.com/illumina Instagram: https://www.instagram.com/illuminainc/ Facebook: https://www.facebook.com/illuminainc TikTok: https://www.tiktok.com/@illuminainc #NGS #CGP #biomarker #Illumina